These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Low exposure to cyclosporine is a risk factor for the occurrence of chronic rejection after kidney transplantation. Citterio F; Torricelli P; Serino F; Foco M; Pozzetto U; Fioravanti P; Castagneto M Transplant Proc; 1998 Aug; 30(5):1688-90. PubMed ID: 9723245 [No Abstract] [Full Text] [Related]
6. Improvement of correlation between oral dose of cyclosporine and cyclosporinemia after substitution of cyclosporine standard presentation by cyclosporine microemulsion one, in 1345 patients with kidney transplantation. Spanish Sandimmune Neoral Conversion Group. Gentil Govantes MA; Gómez Ullate P; Errasti P; Fernández Fresnedo G; Capdevila L; Sanz Guajardo A; Cubero JJ Transplant Proc; 1998 Aug; 30(5):1658-9. PubMed ID: 9723231 [No Abstract] [Full Text] [Related]
7. Modification of the pharmacokinetics of cyclosporine A and metabolites by the concomitant use of Neoral and diltiazem or ketoconazol in stable adult kidney transplants. Foradori A; Mezzano S; Videla C; Pefaur J; Elberg A Transplant Proc; 1998 Aug; 30(5):1685-7. PubMed ID: 9723244 [No Abstract] [Full Text] [Related]
8. Optimization of cyclosporine therapy with abbreviated area under the curve method in renal transplant. Yang WC; Chen YF; King KL; Wu TH; Chen Hsu RY ; Tang JJ; Loong CC; Chou MH; Lin MF; Lui WY Transplant Proc; 2000 Nov; 32(7):1685-7. PubMed ID: 11119892 [No Abstract] [Full Text] [Related]
9. Limited sampling strategy to estimate exposure to cyclosporine A in renal allograft recipients treated with Sandimmune-Neoral. Serafinowicz A; Gaciong Z; Baçzkowska T; Rell K; Lao M; Wałaszewski J Transplant Proc; 1996 Dec; 28(6):3138-9. PubMed ID: 8962216 [No Abstract] [Full Text] [Related]
10. Convenience of level of cyclosporine-Neoral at time 3 to determine the area under curve in renal transplant. Rial MC; Frias S; Argento J; Tessler J; Casadei D Transplant Proc; 1997; 29(1-2):292-3. PubMed ID: 9123001 [No Abstract] [Full Text] [Related]
11. The impact of cyclosporin formulation on clinical outcomes. Holt DW; Johnston A Transplant Proc; 2000 Nov; 32(7):1552-5. PubMed ID: 11119831 [No Abstract] [Full Text] [Related]
12. Study of neoral kinetics in adult renal transplantation treated with diltiazem. Mezzano S; Flores C; Ardiles L; Foradori A; Elberg A Transplant Proc; 1998 Aug; 30(5):1660-2. PubMed ID: 9723232 [No Abstract] [Full Text] [Related]
15. Early achievement of target cyclosporine levels during initial post-transplant period with a novel dosing strategy. Chueh SC; Lai MK Transplant Proc; 1998 Aug; 30(5):1681-2. PubMed ID: 9723242 [No Abstract] [Full Text] [Related]
17. Study of circadian variation of cyclosporine pharmacokinetics. Milanian I; Ghods AJ; Mahmoudian M; Proushani-Nia F; Nejad Gashti H; Abdi E; Abbasi M Transplant Proc; 1997 Nov; 29(7):2930-1. PubMed ID: 9365618 [No Abstract] [Full Text] [Related]
18. Sandimmun and Neoral treatment: pharmacokinetics and kidney function in paediatric and adolescent renal transplant. De Palma MT; Giordano M; Colella V; Palumbo F; De Nicolo VE; Caringella DA Transplant Proc; 1998 Aug; 30(5):1677. PubMed ID: 9723239 [No Abstract] [Full Text] [Related]
19. Abbreviating area under the curves further: a practical approach to monitoring extended pharmacokinetics with Neoral. Sindhi R; Shah J; Foley L; Bucsis J; Kyryliuk T; Baliga PK; Rajagopalan PR Transplant Proc; 1998 Jun; 30(4):1197-8. PubMed ID: 9636485 [No Abstract] [Full Text] [Related]
20. Optimization of cyclosporine therapy in renal transplantation. Ponticelli C Transplant Proc; 1998 Aug; 30(5):1718-20. PubMed ID: 9723254 [No Abstract] [Full Text] [Related] [Next] [New Search]